As of May 27, 2025, E-Therapeutics PLC has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $9.00, this represents a potential upside of -1052.3%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -759.6% |
| Potential Upside (10-year) | -1052.3% |
| Discount Rate (WACC) | 5.7% - 7.9% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 01-2023 | 0 | 0% |
| 01-2024 | 1 | 5% |
| 01-2025 | 1 | 16% |
| 01-2026 | 1 | 13% |
| 01-2027 | 1 | 12% |
| 01-2028 | 1 | 14% |
| 01-2029 | 1 | 12% |
| 01-2030 | 1 | 11% |
| 01-2031 | 1 | 14% |
| 01-2032 | 1 | 10% |
| 01-2033 | 1 | 12% |
Net profit margin is expected to improve from -1742% in 01-2023 to -1696% by 01-2033, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 01-2023 | (8) | -1742% |
| 01-2024 | (8) | -849% |
| 01-2025 | (10) | -988% |
| 01-2026 | (11) | -1115% |
| 01-2027 | (12) | -1244% |
| 01-2028 | (14) | -1419% |
| 01-2029 | (16) | -1596% |
| 01-2030 | (18) | -1696% |
| 01-2031 | (20) | -1696% |
| 01-2032 | (22) | -1696% |
| 01-2033 | (25) | -1696% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 67% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 01-2024 | 0 |
| 01-2025 | 0 |
| 01-2026 | 0 |
| 01-2027 | 0 |
| 01-2028 | 0 |
| 01-2029 | 1 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 0 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2024 | (10) | (2) | 0 | 0 | (9) |
| 2025 | (12) | (2) | 0 | 0 | (10) |
| 2026 | (14) | (2) | 0 | 0 | (12) |
| 2027 | (15) | (3) | 0 | 0 | (13) |
| 2028 | (18) | (3) | 1 | 0 | (15) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -759.6% |
| 10-Year DCF (Growth) | 0.00 | -1052.3% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is E-Therapeutics PLC (ETX.L) a buy or a sell? E-Therapeutics PLC is definitely a sell. Based on our DCF analysis, E-Therapeutics PLC (ETX.L) appears to be overvalued with upside potential of -1052.3%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $9.00.